Free Trial
ASX:PXS

Pharmaxis (PXS) Stock Price, News & Analysis

Pharmaxis logo

About Pharmaxis Stock (ASX:PXS)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
721,139 shs
Average Volume
N/A
Market Capitalization
A$20.23 million
P/E Ratio
N/A
Dividend Yield
6.41%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PXS Stock News Headlines

Elon calling
Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corporate history. Tesla insiders are preparing for a dramatic new product launch – not driverless cars – that could change everything. You're running out of time to prepare.tc pixel
Canaccord Genuity Sticks to Their Buy Rating for Pharmaxis Ltd (SNT)
Pharmaxis Ltd Highlights Product Pipeline and Risks
Syntara bolsters financial position with R&D tax incentive
See More Headlines

PXS Stock Analysis - Frequently Asked Questions

Pharmaxis Ltd (ASX:PXS) posted its earnings results on Thursday, February, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. Pharmaxis had a negative trailing twelve-month return on equity of 143.13% and a negative net margin of 161.24%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharmaxis investors own include Atara Biotherapeutics (ATRA), CRISPR Therapeutics (CRSP), Acasti Pharma (ACST), American Woodmark (AMWD), Guardion Health Sciences (GHSI), Incannex Healthcare (IHL) and XPO (XPO).

Company Calendar

Last Earnings
2/14/2019
Today
10/09/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Transportation
Current Symbol
ASX:PXS
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A($0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
0.21
Net Income
-A$18.43 million
Net Margins
-161.24%
Pretax Margin
N/A
Return on Equity
-143.13%
Return on Assets
-48.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.21
Quick Ratio
14.73

Sales & Book Value

Annual Sales
A$11.89 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
1.32
Book Value
A$0.00 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
722,610,000
Free Float
N/A
Market Cap
A$20.23 million
Optionable
Not Optionable
Beta
0.64
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (ASX:PXS) was last updated on 10/10/2025 by MarketBeat.com Staff
From Our Partners